Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

SHA: 688712

    • Home
    • SHA: 688712
Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026

Insight Lifetech, a Qiming Venture Partners‑backed innovative medical device manufacturer, has listed on the Shanghai...

Recent updates

  • Novartis Commits RMB 3.3 Billion China Investment – Expands Radioligand Therapy Ecosystem with Policy Push
  • Henlius Biotech’s HLX18 Wins NMPA Approval – Nivolumab Biosimilar Enters Phase I Solid Tumor Trials in China
  • Everest Medicines Acquires Etripamil Rights from Corxel – USD 50 Million Deal for First‑in‑Class PSVT Nasal Spray in Greater China
  • Lepu Biopharma Wins NMPA Approval for Perioperative HNSCC Trial – First‑in‑World EGFR ADC + PD‑1 Combination Advances to Clinic
  • Henlius Biotech Reports 2025 Revenue Growth 16.5% – Ex‑China Business Doubles as Global Expansion Accelerates
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Novartis Commits RMB 3.3 Billion China Investment – Expands Radioligand Therapy Ecosystem with Policy Push

Company Drug

Henlius Biotech’s HLX18 Wins NMPA Approval – Nivolumab Biosimilar Enters Phase I Solid Tumor Trials in China

Company Deals

Everest Medicines Acquires Etripamil Rights from Corxel – USD 50 Million Deal for First‑in‑Class PSVT Nasal Spray in Greater China

Company Drug

Lepu Biopharma Wins NMPA Approval for Perioperative HNSCC Trial – First‑in‑World EGFR ADC + PD‑1 Combination Advances to Clinic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.